Cited by 1,171Gastric Cancer Management and OutcomesColorectal Cancer Treatments and StudiesIntraperitoneal and Appendiceal Malignancies

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data

Open access

Wagner, Anna D., Grothe, Wilfried, Haerting, Johannes, Kleber, Gerhard, Grothey, Axel, Fleig, Wolfgang E.·2006·Journal of Clinical Oncology

DOI 10.1200/jco.2005.05.0245

Open this paper in CoChat — free account Open PDF

Abstract

Purpose: This systematic review and meta-analysis were performed to assess the efficacy and tolerability of chemotherapy in patients with advanced gastric cancer. Methods: Randomized phase II and III clinical trials on first-line chemotherapy in advanced gastric cancer were identified by electronic searches of Medline, Embase, the Cochrane Controlled Trials Register, and Cancerlit; hand searches of relevant abstract books and reference lists; and contact to experts. Meta-analysis was performed using the fixed-effect model. Overall survival, reported as hazard ratio (HR) with 95% CI, was the primary outcome measure. Results: Analysis of chemotherapy versus best supportive care (HR = 0.39; 95% CI, 0.28 to 0.52) and combination versus single agent, mainly fluorouracil (FU) -based chemotherapy (HR = 0.83; 95% CI = 0.74 to 0.93) showed significant overall survival benefits in favor of chemotherapy and combination chemotherapy, respectively. In addition, comparisons of FU/cisplatin-containing regimens with versus without anthracyclines (HR = 0.77; 95% CI, 0.62 to 0.95) and FU/anthracycline-containing combinations with versus without cisplatin (HR = 0.83; 95% CI, 0.76 to 0.91) both demonstrated a significant survival benefit for the three-drug combination. Comparing irinotecan-containing versus nonirinotecan-containing combinations (mainly FU/cisplatin) resulted in a nonsignificant survival benefit in favor of the irinotecan-containing regimens (HR = 0.88; 95% CI, 0.73 to 1.06), but they have never been compared against a three-drug combination. Conclusion: Best survival results are achieved with three-drug regimens containing FU, an anthracycline, and cisplatin. Among these, regimens including FU as bolus exhibit a higher rate of toxic deaths than regimens using a continuous infusion of FU, such as epirubicin, cisplatin, and continuous-infusion FU.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2005.05.0245

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Practical Statistics for Medical Research.
Walter, S., & Altman, D. G. (1992) · Biometrics · doi:10.2307/2532320 · Cited by 11,666
Practical Statistics for Medical Research
Altman, D. G. (1990) · doi:10.1201/9780429258589 · Cited by 10,668
Chemotherapy for advanced gastric cancer
Wagner, D., Syn, N. L. X., Moehler, M. H., Grothe, W., Yong, W. P., Tai, B., Ho, J., & Unverzagt, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004064.pub4 · Cited by 1,399
Self-citation
Palliative Care
Sepulveda, C. R., Marlin, A., Yoshida, T., & Ullrich, A. (2002) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(02)00440-2 · Cited by 1,295
A Survey of Exact Inference for Contingency Tables
Agresti, A. (1992) · Statistical Science · doi:10.1214/ss/1177011454 · Cited by 1,132
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment
Grothey, A., Sargent, D., Goldberg, R. M., & Schmoll, H.-J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.037 · Cited by 1,070
Self-citation
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.
Webb, A., Cunningham, D., Scarffe, J. H., Harper, P., Norman, A. R., Joffe, J., Hughes, M., Mansi, J., Findlay, M., Hill, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.261 · Cited by 868
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer
Glimelius, B. L. G., Ekström, K., Hoffman, K., Graf, W. D., Sjödén, P., Haglund, U., Svensson, C., Enander, L. K., Linné, T., Sellsröm, H., et al. (1997) · Annals of Oncology · doi:10.1023/a:1008243606668 · Cited by 844
Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer
Pyrhönen, S. O., Kuitunen, T., Nyandoto, P., & Kouri, M. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.114 · Cited by 786
Systematic reviews of evaluations of prognostic variables
Altman, D. G. (2001) · BMJ · doi:10.1136/bmj.323.7306.224 · Cited by 756

Show all 51 references

Research works printed but not linked: 1

10.1001/jama.1985.03350380077025 · DOI

Sorted by citations

Items 901–1,000 of 1,000

Efficacy and safety of ramucirumab plus paclitaxel therapy for advanced gastric cancer patients treated previously with docetaxel-containing chemotherapy
Kakuta, T., Yabusaki, H., Bamba, T., Aizawa, M., Nogami, H., Nomura, T., Matsuki, A., Maruyama, S., Takii, Y., & Nakagawa, S. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01845-0 · Cited by 3
“This study assessed the clinical outcomes of RAM plus PTX therapy by * Tomoyuki Kakuta to-k117@med.niigata-u.ac.jp 1 Department of Digestive Surgery, Niigata Cancer Center Hospital, 1-757 Asahimachi-dori, Niigata City 951-8510, Japan 1 3 comparatively evaluating in advanced gastric cancer patients who had or had not p…”
Background
An observational retrospective analysis of the main metastatic site and corresponding locoregional treatment as a prognostic factor in metastatic gastric cancer
Giampieri, R., Cantini, L., Prete, M. D., Bittoni, A., Giglio, E., Mandolesi, A., Maccaroni, E., Lanese, A., Meletani, T., Baleani, M. G., et al. (2021) · Oncology Letters · doi:10.3892/ol.2021.12528 · Cited by 3
“In this group of patients, palliative chemotherapy represents the mainstay of treatment (3).”
Background
GASTROINTESTINAL CANCERS
(2007) · Cancer Investigation · doi:10.1080/07357900701571726 · Cited by 3
“Response rates for combination systemic chemotherapy had been also poor (6, 7).”
Apatinib as a Third-Line Treatment for HER2-Positive Metastatic Gastric Cancer: A Multi-Center Single-Arm Cohort Study
Zhang, X., Huo, H., Nie, Y., Xue, J., Yuan, Z., & Zhang, Z. (2022) · Journal of the Korean Gastric Cancer Association · doi:10.5230/jgc.2022.22.e33 · Cited by 3
“Nevertheless, some patients with HER2+ mGC may fail to respond to these treatments [10-14].”
Background
Role of low dose capecitabine combined to irinotecan in advanced and metastatic gastric cancer
Farhat, F., Kattan, J. G., Chahine, G. Y., Younes, F. C., Nasr, F. L., Mroue, R. M., & Ghosn, M. G. (2009) · Medical Oncology · doi:10.1007/s12032-009-9275-z · Cited by 3
“that the triplet regimens combining anthracyclines, cisplatin, and 5-FU are the most active regimens [3, 4]. However, toxicity is substantially high in almost all reported phase II and III trials for combination chemotherapy [ 4 ].”
BackgroundResultInfluential
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastrointestinal cancers: fad or standard of care?
Teo, M., & Tan, G. H. (2018) · Singapore Medical Journal · doi:10.11622/smedj.2018025 · Cited by 3
“They are found intraoperatively during planned surgical resection in 10%–20% of patients, will develop in 20%–50% of patients after curative surgery(15) and are the cause of death in 60% of gastric cancer patients.(16) Traditionally, PM with a gastric origin are considered distant metastases.”
Background
Phase II study of S‐1 and irinotecan combination chemotherapy as a first‐line therapy for patients with advanced gastric cancer. Korean Cancer Study Group Protocol ST05‐02
Kang, H. J., Cho, S. H., Oh, S. J., Yang, S. H., Lee, M. H., Song, E., Chung, H. C., Na, I. I., & Ryoo, B. (2009) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2009.01191.x · Cited by 3
Antiangiogenic therapies in gastric cancer: trusting the pathway
Alsina, M., Hierro, C., & Tabernero, J. M. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw541 · Cited by 3
Efficacy of Systemic Oncological Treatments in Patients With Advanced Esophageal or Gastric Cancers at High Risk of Dying in the Middle and Short Term: An Overview of Systematic ReviewsPreprint
Santero, M., Bracchiglione, J., Acosta‐Dighero, R., Meade, A.-G., Antequera, A., Auladell-Rispau, A., Quintana, M. J., Requeijo, C., Rodríguez-Grijalva, G., Dorantes-Romandía, R., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-151401/v1 · Cited by 3
Therapeutic Frontiers in Gastroesophageal Cancer: Contemporary Concepts in Management and Therapy
Peshin, S., Takrori, E., Kodali, N. A., Bashir, F., Gibson, M. K., & Singal, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311424 · Cited by 3
“Evidence consistently supports a survival benefit with chemotherapy, and platinum-based combinations remain the first-line standard for advanced disease [50,51].”
Modified Epirubicin, cisplatin, and 5-FU regimen as first-line chemotherapy in metastatic gastric or gastroesophageal junction adenocarcinoma: A Phase II study
Babu, G., Chaudhuri, T., Lakshmaiah, K., Dasappa, L., Jacob, L. A., Babu, M., Rudresha, A. H., Lokesh, K. N., & Rajeev, L. K. (2019) · South Asian Journal of Cancer · doi:10.4103/sajc.sajc_146_18 · Cited by 2
“showed an improvement in weighted average survival of approximately 2 months with addition of anthracycline to CF regimen, and ECF became the reference standard for advanced/metastatic gastric cancer in many countries.[11]”
Method
Case Report: A rare synchronous multiple gastric carcinoma achieved progression-free disease through NGS-guided serial treatment
Shao, X., Yin, J., Wang, D., Huang, E., Zhang, Y., Yin, J. C., Huang, C., Wu, H., & Wu, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1195837 · Cited by 2
RETRACTED: ASAP1 protein macromolecule promotes the growth and development of gastric cancer cells and the remodeling of F-actin cytoskeleton: Expression of VEGF and HIF-1 α proteins
Gao, H., Qin, L., Shi, H., Song, H., Li, Z., Xue, Y., & Liu, T. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.144589 · Cited by 2
Retracted
Efficacy and tolerability of docetaxel and cisplatin plus S-1 for advanced gastric cancer.
Luo, H., Yu, Z.-H., Gao, H., Guan, C., & Xu, M. M. (2013) · PubMed · Cited by 2
Efficacy and Safety of Docetaxel Plus Oxaliplatin and Capecitabine in the First Line Treatment of Advanced Gastric Adenocarcinoma
Liu, Y., Ye, Z.-B., Xi, W., Ma, T., Shi, M., Yang, L., Zhu, Z., & Zhang, J. (2013) · BioMed Research International · doi:10.1155/2013/971096 · Cited by 2
Gastric cancer: Environmental risk factors, treatment, and prevention
Woodman, A., Akhtar, M., Al-Jamea, L. H., Sagher, M., & Sager, M. (2020) · Ibnosina Journal of Medicine and Biomedical Sciences · doi:10.4103/ijmbs.ijmbs_104_20 · Cited by 2
Maagcarcinoom
Siersema, P. D. (2013) · Huisarts en Wetenschap · doi:10.1007/s12445-013-0325-6 · Cited by 2
Apatinib inhibits the proliferation of gastric cancer cells via the AKT/GSK signaling pathway in vivo
Chen, Y., Chen, N., Xu, J., Wang, X., Wei, X., Tang, C., Duanmu, Z., & Shi, J. (2021) · Aging · doi:10.18632/aging.203458 · Cited by 2
“The regular outcomes of conventional combination chemotherapies, including capecitabine, oxaliplatin, and 5-FU, remain poor, manifesting that the average OS of these patients is no more than 12 months and the 5-year survival value is under 10% [27, 28].”
Background
SOCRATE-PRODIGE 55 trial: A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer
Boisteau, É., François, É., Aparicio, T., Malicot, K. L., Boulahssass, R., Lecomte, T., Laurent‐Puig, P., Guiu, B., Paillaud, É., Galais, M., et al. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2022.03.001 · Cited by 2
Phase I/II studies of combination chemotherapy with S-1 and platinum in patients with previously untreated metastatic or recurrent gastric cancer
Kang, Y. (2009) · Gastric Cancer · doi:10.1007/s10120-008-0472-9 · Cited by 2
“Although combination chemotherapy has been studied extensively, there is no internationally accepted standard of care for patients with advanced gastric cancer [4–7].”
Background
Long Term Complete Remission in Advanced Gastric Adenocarcinoma With Docetaxel, Oxaliplatin and Capecitabine Combination Regimen
Goel, G. (2012) · World Journal of Oncology · doi:10.4021/wjon469w · Cited by 2
Enfoque terapéutico del cáncer gástrico. Revisión de la literatura
Torregroza, M., & Guarnizo, C. (2011) · Revista Colombiana de Cancerología · doi:10.1016/s0123-9015(11)70078-6 · Cited by 2
Tratamento paliativo do adenocarcinoma gástrico
Souza, F. D. O., Antunes, L. C. M., & dos Santos, L. H. R. (2011) · ABCD Arquivos Brasileiros de Cirurgia Digestiva (São Paulo) · doi:10.1590/s0102-67202011000100016 · Cited by 2
A Review of Docetaxel: Its Use in the Treatment of Gastric Cancer
Inno, A., Basso, M., Cassano, A., & Barone, C. A. (2010) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s5191 · Cited by 2
Phase I and II Clinical Trials for Gastric Cancer
Khushalani, N. I. (2011) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2011.09.006 · Cited by 2
“Systemic chemotherapy improves survival compared with best supportive care and combination chemotherapy yields higher response rates compared with single-agent treatment.(8,9) This treatment is typically recommended for patients with a good performance status.”
Background
Systemic therapy for gastric cancer and adenocarcinoma of the gastroesophageal junction: present status and future directions
Richards, D., Boehm, K. A., & Anthony, S. P. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.7.1059 · Cited by 2
“[13] has shown a fairly significant overall survival benefit (p < 0.”
Background
RETRACTED ARTICLE: Joint detection of ERCC1, TUBB3, and TYMS guidance selection of docetaxel, 5-fluorouracil and cisplatin (DDP) individual chemotherapy in advanced gastric cancer patients
Luo, Y., Li, Z., Cui, S., Shen, C., Zhao, J., Wu, M., Li, Y., Wang, M., Chen, R., Liu, Z., et al. (2014) · European journal of medical research · doi:10.1186/s40001-014-0050-z · Cited by 2
“Although many chemotherapy regimens in randomized studies have been examined, there is no international standard for gastric cancer treatment [5,9].”
Retracted
Novel Targeted Therapy for Advanced Gastric Cancer
Xu, H. (2015) · Biochemistry & Pharmacology Open Access · doi:10.4172/2167-0501.1000154 · Cited by 2
Systemic therapy for advanced gastric cancer
Yeo, W. (2010) · Cited by 2
Treatment of Advanced Gastric Cancer with Cetuximab plus Chemotherapy followed by Surgery. Report of a Case
Casadei, R., Rega, D., Pinto, C., Monari, F., Ricci, C., Sciannamea, G., & Minni, F. (2009) · Tumori Journal · doi:10.1177/030089160909500627 · Cited by 2
Current practice for gastric cancer treatment in Ukraine
Sydiuk, A. (2017) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2017.04.07 · Cited by 2
“Randomized studies reveal that PCT is the only way to improve the GC patients’ quality of life, as well as to raise life expectancy from 4–5 to 10–12 months compared with symptomatic treatment (22).”
Survival benefit of anti-angiogenic agents in patients with previously treated advanced gastric or gastroesophageal junction cancer: a meta-analysis
Kim, J. H., Kim, H. S., Kim, B. J., & Jang, H. J. (2017) · Oncotarget · doi:10.18632/oncotarget.18314 · Cited by 2
“Combination of fluoropyrimidine and platinum has been established worldwide as the first-line therapy for advanced GC [5].”
Background
Survival outcomes with docetaxel, oxaliplatin, and fluorouracil regimen for the treatment of metastatic gastric adenocarcinoma: A single-center experience
Patil, P. P., Gupta, V. G., Rangaraju, R., Abbas, W., Acharya, R., & Pandit, A. (2020) · Oncology Journal of India · doi:10.4103/oji.oji_8_20 · Cited by 2
Monoclonal Antibody Therapy Against Gastrointestinal Tract Cancers
Gouda, G., Gupta, M. K., Donde, R., Behera, L., & Vadde, R. (2020) · Diagnostics and therapeutic advances in GI malignancies · doi:10.1007/978-981-15-6487-1_7 · Cited by 2
Metabolic dysregulation in cancer progression
Arfin, S., Agrawal, K., Kumar, A., Kumar, A. J., Rathi, B., & Kumar, D. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99879-6.00008-0 · Cited by 2
Second-Line Chemotherapy in Gastric Cancer: a Retrospective Study
Yıldırım, S., & Özveren, A. (2023) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-022-01695-4 · Cited by 2
“The most common treatment for metastatic patients is palliative chemotherapy, which aims to prolong survival and improve their quality of life [2] .”
Background
First-Line Systemic Therapy Outcomes in Western Population with Locally Advanced and Metastatic Gastric Cancer—A Systematic Review
Marupuru, S., Arku, D., Axon, D. R., Zapata, L. V., Yaghoubi, M., Slack, M. K., & Warholak, T. L. (2023) · Gastroenterology Insights · doi:10.3390/gastroent14040037 · Cited by 2
“An older systematic review by Wagner, 2006 [54], assessed ﬁrst-line chemotherapy in patients with advanced gastric cancer and included overall survival as the primary outcome.”
Background
Benefit of a multimodal approach combining chemotherapy and surgery in oligometastatic gastric cancer: experience from a tertiary referral center
Maratta, M. G., Vitale, A., Basso, M., Vivolo, R., Monte, E. D., Biondi, A., Giorgio, A. D., Rosa, F., Tondolo, V., Agnes, A., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1343596 · Cited by 2
Does combining docetaxel with cisplatin and fluorouracil improve clinical benefit in advanced gastroesophageal cancer?
Ratnayake, G., & Cunningham, D. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1044 · Cited by 2
“A meta-analysis that included trials on the Cochrane Controlled Trials register reported the best survival results in advanced gastric cancers when CF was combined with an anthracycline”
Method
Controlled thermal-sensitive liposomes release on a disposable microfluidic device
Meng, L., Deng, Z., Niu, L., Cai, F., & Zheng, H. (2015) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc.2015.7319737 · Cited by 2
Chemotherapy for Esophageal Adenocarcinoma
Lam, K. O., & Kwong, D. L. �. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7734-5_3 · Cited by 2
A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
Lui, A. G. A., Mulder, K. E., Brezden‐Masley, C., Vickers, M. M., Monzon, J. G., Kennecke, H. F., Goel, R., Vos, L. J., Ghosh, S., Marginean, H., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0599-4 · Cited by 2
Metachronous Skin Metastasis of Gastric Cancer: Case Report
Rakka, M. (2019) · Juniper Online Journal of Case Studies · doi:10.19080/jojcs.2019.10.555793 · Cited by 2
Comparison of Efficacy of Aspirin Plus EOX vs. EOX Alone in Patients with Locally Advanced and Metastatic Gastric Cancer: a Randomized Clinical Trial
Jafa, E., Charles, L., Nisha, Y., Kate, V., Kayal, S., Ganesh, R. N., Chakkalakkoombil, S. V., Ganesan, P., Penumadu, P., & Dubashi, B. (2022) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-022-00845-9 · Cited by 2
“The prognosis of patients with advanced inoperable and metastatic gastric cancer remains guarded, with a median survival ranging from 7 to 10 months in most larger clinical studies [8].”
Background
How Closely Should We Follow Gastric Cancer Patients Following Surgical Resection?
Yoon, S. S. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1416-2 · Cited by 2
Phase II Study of Irinotecan plus Leucovorin and Bolus 5-Fluorouracil as First- or Second-Line Chemotherapy in Patients with Advanced Gastric or Esophageal-Gastric Junction Adenocarcinoma
Koutras, A., Gerolymos, M. K., Kontogeorgou, E., Iconomou, G., Vourli, G., Tsiata, E., Makatsoris, T., Chrysanthopoulos, C. J., & Kalofonos, H. P. (2007) · Journal of Chemotherapy · doi:10.1179/joc.2007.19.6.724 · Cited by 2
Career Advice for Oncology Trainees
Rosenthal, M. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0654 · Cited by 2
Molecular-targeted therapy for advanced gastric cancer
Song, H., Zhu, J., & Lu, D. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011461 · Cited by 2
In Reply
Wagner, D., Fleig, W. E., & Haerting, J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.9432 · Cited by 2
Self-citation
Consensus Guideline for the Management of Gastric Cancer with Synchronous Peritoneal MetastasesPreprint
PSM Writing Group, & Turaga, K. K. (2024) · medRxiv · doi:10.1101/2024.04.10.24305456 · Cited by 2
Does Neoadjuvant Chemotherapy Increase the Survival in Patients with Locally Advanced Gastric Cancer Patients? – A Real‑World Evidence
Janarthinakani, M., Kalaiselvi, S., Priyadarshini, R., Arun, S., Shashidhar, K., Krishnakumar, R., Manjunath, N., Roopa, S., & Raman, S. G. (2020) · Indian Journal of Medical and Paediatric Oncology · doi:10.4103/ijmpo.ijmpo_188_20 · Cited by 1
“[18] Although the FAMTX trial[19] could not demonstrate better outcomes for neoadjuvant chemotherapy, a meta-analysis on chemotherapy concluded that chemotherapy was advantageous in advanced gastric cancer.[20]”
Result
Evaluation of the efficiency of perioperative chemotherapy in the complex treatment of gastric cancer
Олегович, М. Е., Привалов, А. В., Kuvaev, S. V., Семикопов, К. В., & Gavrishkin, I. A. (2021) · Ural Medical Journal · doi:10.52420/2071-5943-2021-20-2-17-22 · Cited by 2
A prospective phase II single-arm study and predictive factor analysis of irinotecan as third-line treatment in patients with metastatic gastric cancer
Yu, N., Huang, S., Zhang, Z., Huang, M., Wang, Y., Zhang, W., Zhang, X., Zhu, X., Sheng, X., Yu, K., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241229433 · Cited by 1
Current status and trends of machine learning applied in clinical research of gastric cancer from 2004 to 2023: global bibliometric and visual analysis
Wang, X., Wu, C., Yue, S., Zhou, M., Zhuo, E., Wu, X., Wang, Y., Chen, B., & Wang, F. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1420517 · Cited by 1
“In recent years, with a deeper understanding of the molecular basis of tumors, targeted therapy has become an effective treatment option (56).”
Inhibition of human gastric cancer growth by cytokine-induced killer cells plus chemotherapy with or without cadonilimab in a mouse xenograft tumor model
Yang, W., Liu, J., Hou, T., Lu, X., & Yang, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1609320 · Cited by 1
“However, chemotherapy alone has limited ef ﬁ cacy in treating GC, with a median overall survival (OS) of 6 – 10 months (3).”
HER2 discordance between primary and metastatic gastric cancer: a systematic review and meta-analysis
de Moraes, F. C. A., Rego, L. H. R. M., Rebelo, T. G., Matheus, G. T. F. U., & Melo, A. C. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04359-9 · Cited by 1
Capecitabine in Combination with Oxaliplatin as First-Line Therapy for Advanced Gastric Cancer: A Case Report
Mazzola, R., Alù, M., Leonardi, V. B., Procopio, G., & Agostara, B. (2011) · Tumori Journal · doi:10.1177/030089161109700120 · Cited by 1
Application of meta-analysis in evidence-based oncology
Lin, X., & Wang, Q. (2008) · Chinese Journal of Clinical Oncology · doi:10.1007/s11805-008-0001-y · Cited by 1
Chemotherapy of Advanced Gastric Cancer
Jung, J. T. (2013) · The Korean Journal of Helicobacter and Upper Gastrointestinal Research · doi:10.7704/kjhugr.2013.13.3.142 · Cited by 1
Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer
Sym, S. J., Hong, J., Jung, M., Park, J., Cho, E. K., Lee, W. K., Chung, M., Kim, H., Lee, J. H., & Shin, D. B. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1912-0 · Cited by 1
Availability of irinotecan in a second-line setting confers survival benefit to patients with advanced gastric cancer refractory to fluoropyrimidine-based regimens
Oba, M., Chìn, K., Kawazoe, Y., Takagi, K., Ogura, M., Shinozaki, E., Suenaga, M., Matsusaka, S., Mizunuma, N., & Hatake, K. (2011) · Oncology Letters · doi:10.3892/ol.2011.241 · Cited by 1
“When GC is advanced, systemic chemotherapy is regarded as crucial in improving patient quality of life and prolonging survival (2-4).”
Background
Treatment for unresectable gastric cancer
Kim, T., Oh, D., & Bang, Y. (2015) · Journal of Korean Medical Association · doi:10.5124/jkma.2015.58.3.209 · Cited by 1
“52) [4].”
Magen- und gastroösopha- geales Übergangskarzinom Diagnostik und Therapieoptionen des frühen bis metastasierten Tumorstadiums Die Adenokarzinome am Übergang vom Magen zum Ösophagus unterscheiden sich biologisch klar von den Magenkarzinomen. In diesem Beitrag stellen wir die beiden Tumorentitäten ein- ander bezüglich Pathogenese, Diagnostik und Therapie gegenüber.
Inauen, R. I., & Ruhstaller, T. (2009) · Cited by 1
Outcomes of advanced gastric cancer in young adult patients treated with first-line combination chemotherapy
Kim, H., & Kim, K. (2015) · International Journal of Cancer Therapy and Oncology · doi:10.14319/ijcto.34.4 · Cited by 1
Systemic therapy for gastric cancer
Khandekar, J. D., & Khandekar, M. J. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511691751.008 · Cited by 1
Long-term survival of a young patient after multi-disciplinary treatment of initially inoperable stomach cancer with metastases to the liver and visceral lymph node
Zakrzewska, I. (2016) · Oncoreview · doi:10.5604/01.3001.0009.5067 · Cited by 1
“Replacement of 5-FU with capecitabin and substitution of oxaliplatin for cisplatin does not adversely affect outcomes, is better tolerated by the patients and does not require intravenous hydration and continuous infusions [3, 4, 11].”
Background
Milestones in gastric cancer
Wöll, E. (2017) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-017-0311-y · Cited by 1
“These data and others were analyzed in a meta-analysis 10 years ago [15].”
Method
The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration
Berretta, M., Romano, C., Francia, R. D., Diviitis, C. D., Canzonieri, V., Caraglia, M., Facchini, G., & Nasti, G. (2017) · Current Cancer Drug Targets · doi:10.2174/1568009617666170208162058 · Cited by 1
Efficacy and Toxicity of Cisplatin and Capecitabine Combination in the First-Line Treatment of Patients with Advanced Gastric Cancer: A Multicenter Study by the Anatolian Society of Medical Oncology
Beneklı, M. (2016) · International Journal of Hematology and Oncology · doi:10.4999/uhod.161429 · Cited by 1
Probiyotik Kaynaklı, Muhtemel Prebiyotik Özelliğe Sahip Ekzopolisakkarit (EPS)’ lerin Biyolojik ve Fonksiyonel Özellikleri
Emre, Ü. T., & Aslım, B. (2018) · SDÜ Tıp Fakültesi Dergisi · doi:10.17343/sdutfd.343111 · Cited by 1
A retrospective analysis of chemotherapy for gastric cancer in later-stage elderly patients
Ina, K., Ina, H., Yoneda, M., Kabeya, M., Yuasa, S., Tomomatsu, Y., & Furuta, R. (2018) · Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics · doi:10.3143/geriatrics.55.244 · Cited by 1
Pathological complete response from oral chemotherapy combined with trans-arterial chemotherapy and embolization in an unresectable gastric cancer patient
Su, Z., Shu, K., Kang, M., & Wang, G. (2019) · Medicine · doi:10.1097/md.0000000000016075 · Cited by 1
“These cases usually suffer a poor prognosis with a median survival time of 5 to 12 months.([2,3]) Fortunately, in recent years some clinical studies found that many unresectable gastric cancer cases could get opportunity for surgery after treatment with chemotherapy, radiotherapy, trans-arterial”
Complicaciones del uso de prótesis metálicas autoexpansibles como paliación de obstrucción maligna del tracto de salida gástrico
Oliveros, R., Bonilla, A., Sánchez, R., & Morales, R. E. P. (2019) · Revista Colombiana de Cancerología · doi:10.35509/01239015.92 · Cited by 1
“Los diferentes tratamientos oncológicos de tipo paliativo que buscan mejorar la calidad de vida y la supervivencia de los pacientes con enfermedad maligna avanzada se encuentran en permanente evolución (12-14).”
Background
Methylenetetrahydrofolate reductase polymorphism and capecitabine-induced toxicity in patients with gastric cancer
Xie, X.-W., Wang, M.-R., & Zhang, Y. (2020) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v19i1.28 · Cited by 1
“It is generally believed that palliative chemotherapy for advanced diseases and perioperative chemotherapy can improve the survival rate and quality of life of GC patients [6].”
Background
Advantages of ypTNM Staging in Post-surgical Prognosis for Initially Unresectable or Stage IV Gastric Cancers
Jeong, G.-S., Lee, I., Park, Y.-S., Kim, B. S., Yoo, M., Yook, J. H., & Kim, B. S. (2020) · Journal of the Korean Gastric Cancer Association · doi:10.5230/jgc.2020.20.e20 · Cited by 1
“patients with stage IV gastric cancer [5], and the addition of a targeted agent, to conventional chemotherapy, can improve prognosis when compared to chemotherapy alone [6,7].”
Background
HER2 Receptor Overexpression in Gastric Adenocarcinoma A Study about a Sampling of 50 Cases in Dakar
Bentefouet, T. L. (2019) · Open Access Journal of Microbiology & Biotechnology · doi:10.23880/oajmb-16000151 · Cited by 1
Treatment with Ramucirumab-paclitaxel in a metastatic gastric cancer patient undergoing hemodialysis
Yang, M., Choi, Y. J., Kim, H. J., Kim, D. Y., & Seol, Y. M. (2021) · Medicine · doi:10.1097/md.0000000000024795 · Cited by 1
“1 first-line therapy.([3]) Based on the result of a randomized phase III trials, ramucirumab monotherapy or in combination with paclitaxel was proven safe and effective for patients with metastatic gastric cancer progressed after a first-line of chemotherapy.”
Background
Gastric Cancer: Advanced/Metastatic Disease
Vita, F. D., Tirino, G., Pompella, L., & Petrillo, A. (2021) · UNIPA Springer series · doi:10.1007/978-3-030-56051-5_36 · Cited by 1
Meta-analysis of three randomized trials of capecitabine plus cisplatin (XP) versus S-1 plus cisplatin (SP) as first-line treatment for advanced gastric cancer
Nishikawa, K., Kawakami, H., Shimokawa, T., Fujitani, K., Tamura, S., Endo, S., Kobayashi, M., Kawada, J., Kurokawa, Y., Tsuburaya, A., et al. (2023) · International Journal of Clinical Oncology · doi:10.1007/s10147-023-02402-1 · Cited by 1
“Combination chemotherapy regimens provide better response rates (RRs) and modest survival benefits compared with single-agent therapies [2].”
Background
Chemotherapy Efficacy and Tolerability in Metastatic Gastric Cancer Patients Aged 75 Years and Older
Sezigin, Y. (2023) · Eurasian Journal of Medical Investigation · doi:10.14744/ejmi.2023.71797 · Cited by 1
“[13] In our study, OS was 8.6 months in those receiving combination therapy and 7.9 months in those receiving monotherapy, and there was no statistically significant difference.”
Influential
Application of Artificial Intelligence in Gastric Cancer
Lee, J.-I. (2023) · Journal of Digestive Cancer Research · doi:10.52927/jdcr.2023.11.3.130 · Cited by 1
Successful treatment with nivolumab in a patient with gastric cancer with severe liver failure resulting from multiple liver metastases: A case report
Ikejiri, F., Yokomizo, K., & Tamura, K. (2024) · Oncology Letters · doi:10.3892/ol.2024.14404 · Cited by 1
Efficacy and Safety of First-Line Palliative Chemotherapy with Fluorouracil Plus Leucovorin, Oxaliplatin, and Docetaxel (FLOT) in HER2-Negative Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Institutional Real-World Experience from Eastern India
Chaudhuri, T., Bankira, J., Upadhyay, A. K., Panda, R., Pandey, V., Mitra, S., & Mukherjee, S. (2024) · South Asian Journal of Cancer · doi:10.1055/s-0044-1791524 · Cited by 1
“14 But later on, in a randomized phase II study including Asian patients, the addition ofepirubicin to a PF combination failed to improve response rate or survival.”
Clinical Use of Cisplatin Liposomes for Patients With Refractory Advanced Cancer
Komura, Y., Kimura, S., Katagiri, T., Hirasawa, Y., Hirayama, M., Okuda, T., Muranishi, H., & Homma, K. (2024) · Cureus · doi:10.7759/cureus.73181
Direct Liver Invasion from a Gastric Adenocarcinoma as an Initial Presentation of Extranodal Tumor Spread
Shah, M., Prasad, A., Rajan, D., Tan, C. B., Shah, M. R., Raghavan, P., & Mustacchia, P. J. (2012) · Case Reports in Medicine · doi:10.1155/2012/651232 · Cited by 1
“Randomized trials on combined chemotherapy agents, such as, cisplatin along with bleomycin or etoposide have demonstrated statistically signiﬁcant improved survival rates over single chemotherapy agents [8, 9].”
Systemic therapy for advanced gastric cancer: a review
Kelsen, D. P. (2007) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(07)80006-2 · Cited by 1
Epirubicin, taxotere and fluorouracil modulated by folinic acid in the treatment of advanced gastric cancer: A phase II study of the Gruppo Oncologico dell’ Italia Meridionale (GOIM)
Giuliani, F., Romito, S., Maiello, E., Capobianco, A. M. L., Carrozza, F., Nugnes, I., Misino, A., Valerio, M. R., Manzione, L., & Colucci, G. (2008) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2008.06.017 · Cited by 1
Pharmacology of Aging and Cancer: How Useful Are Pharmacokinetic Tests?
Lichtman, S. M. (2013) · Interdisciplinary topics in gerontology and geriatrics · doi:10.1159/000343618 · Cited by 1
Clinical management patterns of advanced and metastatic gastro‐oesophageal carcinoma after fluoropyrimidine/platinum treatment in France, Germany, Spain and the United Kingdom
Brown, J., Liepa, A. M., Bapat, B., Madhwani, S., Lorenzen, S., García‐Foncillas, J., Candrilli, S. D., & Kaye, J. A. (2019) · European Journal of Cancer Care · doi:10.1111/ecc.13213 · Cited by 1
Impact of Oxaliplatin-Induced Neuropathy on Subsequent Paclitaxel for Advanced Gastric Cancer
Sato, J., Iwasa, S., Honma, Y., Takashima, A., Okita, N. T., Kato, K., Hamaguchi, T., Yamada, Y., & Boku, N. (2020) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2020.119045 · Cited by 1
Role of Specific Phytochemicals Against Gastrointestinal Malignancies
Dariya, B., Merchant, N., & Nagaraju, G. P. (2020) · Springer eBooks · doi:10.1007/978-3-030-48405-7_1 · Cited by 1
Where to Start and What to Do Next: The Sequencing of Treatments in Metastatic Esophagogastric Cancer
Mamdani, H. M., & Jalal, S. I. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_321243 · Cited by 2
Outcomes in patients with metastatic gastric cancer: a surveillance, epidemiology, and end results program (SEER) database analysis
Li, W., Tang, Y., Wang, D., & Li, J. (2023) · All Life · doi:10.1080/26895293.2023.2288532 · Cited by 1
Multimodality Therapy in Gastric Cancer
Malhotra, U., & Fong, M. K. (2014) · Springer eBooks · doi:10.1007/978-3-319-09342-0_9 · Cited by 1
“conducted a meta-analysis regarding the effects of chemotherapy on advanced gastric cancer and showed that the combination of chemotherapy agents improved overall survival by 17 % [ 24 ].”
BackgroundInfluential
Möglichkeiten der systemischen Therapie in metastasierten Stadien des Magenkarzinoms
Wagner, D., & Stahl, M. (2008) · Der Onkologe · doi:10.1007/s00761-008-1338-9 · Cited by 1
New horizons for gastric cancer: commentary
Macdonald, J. S., & Cervantes, A. M. R. (2006) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(06)70001-5 · Cited by 1
Upper Gastrointestinal Malignancies: A New Era in Clinical Colorectal Cancer
Hawkes, E. A., Chau, I., Ilson, D. H., & Cunningham, D. (2009) · Clinical Colorectal Cancer · doi:10.3816/ccc.2009.n.030 · Cited by 1
Phase II study of oxaliplatin, UFT, and leucovorin in patients with metastatic gastric cancer
Siemerink, E., Drenth, A. F. J., Mulder, N. H., Plukker, J. T. M., & Hospers, G. A. P. (2010) · Gastric Cancer · doi:10.1007/s10120-010-0545-4 · Cited by 1
Drug Development in Advanced Esophagogastric Cancer: The Art of Extrapolation
Punt, C. J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.4923 · Cited by 1
Analytics for Improved Cancer Screening and Treatment
Silberholz, J. (2015) · DSpace@MIT (Massachusetts Institute of Technology) · Cited by 1

Authors: Wagner, A. D., Grothe, W., Haerting, J., Kleber, G., Grothey, A., & Fleig, W. E.
Affiliations: From the First Department of Medicine, Coordinating Centre for Clinical Trials, Department of Medicine IV, and Institute of Medical Epidemiology, Biostatistics and Informatics, Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany; and Mayo Clinic College of Medicine, Rochester, MN
Mayo Clinic (US)
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2006-06-20
Volume: 24
Issue: 18
Pages: 2903-2909
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2005.05.0245
OpenAlex: W2145390243
Cited by: 1,171
References: 51
Citations by year: 2026: 7 · 2025: 15 · 2024: 26 · 2023: 28 · 2022: 34 · 2021: 64 · 2020: 55 · 2019: 54 · 2018: 69 · 2017: 89 · 2016: 72 · 2015: 84 · 2014: 105 · 2013: 92 · 2012: 77
FWCI: 9.54
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: American Society of Clinical Oncology
Bundesministerium für Bildung und Forschung (01GH0105)
Topics: Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
Keywords: advanced gastric cancer, first-line chemotherapy, 5-fluorouracil, cisplatin, anthracyclines, irinotecan, combination chemotherapy, overall survival, best supportive care, epirubicin, chemotherapy toxicity
MeSH terms: Antineoplastic Combined Chemotherapy Protocols, Humans, Stomach Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks